Direct Meds Reviews: The $99 NAD+ Is One Month Only

The one-sentence version

Direct Meds sells NAD+ at $199/mo for 500 mg and $249/mo for 1000 mg, month-to-month, with no subscription and no automatic billing — and advertises it at "starting at $99," which is the first month after a promotion. The underlying structure is genuinely clean; the headline is not, and neither is the pharmacy story, because two Direct Meds pages name two different compounding sections. It grades A, 14 out of 14, tied for the highest score here, computed from published terms alone and blind to who pays us.

What it is, and who it's for

Direct Meds is a compounded telehealth operator best known for GLP-1s, which also runs an Anti-Aging category of its own: NAD+ injection at two strengths, sermorelin injection, and a peptide skin cream. A one-minute qualifier is followed by payment for the first month, then a telehealth visit and a clinician review "expected… within 24 hrs and often less than 5 hrs." It holds LegitScript certification and publishes a medical director described as "a practicing physician [who] has reviewed our doctor and pharmacy network."

The buyer this suits wants a compounded protocol with no membership, no access fee and — unusually — no recurring charge at all. See longevity clinics vs lab memberships.

What it actually costs

All figures verified on directmeds.com on 26 July 2026.

NAD+, in Direct Meds' own words: "For NAD+ Injections, we charge $249/month for 1000mg and $199/month for 500mg. For a limited time you get $100 off your first month—just $99 for 500mg or $69 off your first month—just $180 for 1000mg." The landing page leads with "Starting at $99" and a "Up to $100 OFF" badge. The $99 is one month.

GLP-1s carry the same shape. "For Semaglutide we charge $297/month. For Tirzepatide we charge $497/month. Our lowest cost option is $249/month for non-injectable sublingual oral medication." The offer page shows those struck through against $147 and $149 — again, first order.

What the monthly figure covers. "Your medication, doctor review, pharmacy compounding, supplies, and 2-day shipping." Telehealth visits are inside it and are priced separately at "normally $99/visit." There is no membership and no access fee, and dose increases do not reprice the plan — "same price, every dose."

There is no auto-billing, which is the best term here. "We believe in clear, honest pricing with no surprise charges or automatic billing. Reorder at your convenience through your Direct Meds Patient Portal." Cancellation is "no contracts for our month to month pricing," by email or phone. In a category built on silent renewals, that is a real consumer protection.

The one unpublished ladder. The same answer adds: "We also offer subscribe and save discounts where customers will agree to a subscription length for stated monthly discount." Those lengths and discounts appear on no public page. If you are quoted one, you are seeing a number this site cannot check.

If you are declined, you are refunded. "If for any reason your prescription is not approved, you will receive a full refund." Note the sequence: you pay for the first month before the intake is reviewed.

Clinical oversight, and the pharmacy problem

Prescriptions follow a telehealth visit with a licensed provider in your state, and Direct Meds publishes nursing staff as a stage of the program — "on-going care & support with Direct Meds Nursing Staff" — which is why it takes the human-support point. Our grading methodology sets that out.

The pharmacy is where it goes wrong, and the fault is specific. The GLP-1 offer page states: "Medications prescribed through Direct Meds are dispensed by U.S.-based 503A compounding pharmacies." The NAD+ page — the page you would actually buy this product from — states: "Medications prescribed through Direct Meds are dispensed by U.S.-based 503B compounding pharmacies… 503B compounding pharmacies are licensed by state pharmacy boards and operate under federal compounding laws."

Those are different regimes, and the NAD+ page's description of the one it names is wrong: 503B outsourcing facilities register with FDA and must comply with current good manufacturing practice; being licensed by a state board of pharmacy is the 503A arrangement¹. Either the NAD+ line is a copy error or the two product lines use different facilities, and a buyer cannot tell which. What is not in doubt is that neither page names a pharmacy, and that compounded drugs of either class are not FDA-approved — "FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"¹.

The FDA warning letter, in proportion

On 9 September 2025, FDA's Center for Drug Evaluation and Research issued a warning letter to directmeds.com, Inc. dba DirectMeds (MARCS-CMS 716822)⁶. That is the entity name verbatim from the letter's recipient block, and it doubles as the citation: search that string in the [FDA's warning-letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) and the record is the first thing you see. FDA's index carries no close-out date against it, so it remains open.

We report that the letter exists, who it names, and when it issued — and stop there. Restating the allegations would be us making the accusation; naming the addressee and the date is us reporting that the FDA made one, which is the only one of the two we are entitled to do on a page that earns a commission from the company. FDA's own copy is a search away and is the source worth reading.

The entity FDA named is the one behind the domain, so there is no question of a similarly-named company being confused for this one. Its scope is worth stating because omitting it would mislead in the other direction: the letter concerns the compounded weight-loss line, not the NAD+ or sermorelin products this review grades. It does not move the grade, and that is a rule rather than a favor: our rubric scores published terms — price, consult, pharmacy disclosure, support and longevity line — and a regulatory factor introduced after seeing which rows it would hit is a rule written to fit a result. Two other providers here hold letters of their own, reported identically and on the same reasoning: see our Sprout Health review and Strut Health review.

It belongs beside the section above rather than filed away from it. The pharmacy contradiction and the warning letter are independent findings about the same underlying thing — how carefully this company describes what it dispenses — and a reader weighing $199 a month is entitled to see them together.

The evidence behind what it sells

The NAD+ page is the most aggressive marketing in our ranking. It promises "Start Aging Backwards," the "fountain of youth peptide," and — as a heading — "Scientifically Proven to Help You Feel Younger, Sharper, and More Alive." Beneath that: "Improve Memory & Focus," "Revitalize Cellular DNA," "support long-term longevity," "~100% bioavailability," and results "Fast — feel energy & clarity in days… starting with your very first dose."

None of that is supported. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness "inconclusive." It also reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for anti-aging or wellness indications at all² — which is the entire product on this page. A 2025 meta-analysis in adults averaging over 60 found NMN and NR did not improve muscle index, grip strength, gait speed or chair-stand time³, and the strongest randomized trial in the field moved six-minute walk distance about 17.6 meters in peripheral artery disease, a disease endpoint rather than an aging one⁴.

The sermorelin line has the same problem: the trial of that exact molecule given nightly to older men found nocturnal growth hormone rose while IGF-1, weight, BMI and DEXA-measured muscle and fat did not move⁵. See NAD+ for longevity, peptides for longevity and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if the marketing is what sold you — "scientifically proven" is not a defensible sentence about this molecule. Skip it if the pharmacy classification matters to you, because Direct Meds gives two answers. And do not budget from the $99: your second month is $199, or $249 if your provider puts you on 1000 mg.

Two operational notes. Service is unavailable in Mississippi, and the compounding disclosure adds Louisiana. And the longevity line is buried: the Anti-Aging catalog lists NAD+ and sermorelin with no prices at all, and the figures live only on a separate funnel page.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Direct Meds takes all of them. One all-in figure per product is published with what it covers named; NAD+ and sermorelin are a real longevity line rather than a GLP-1 shop with a badge; the telehealth visit is inside the price; nursing support is published as part of the program; and a 503A claim appears on a surface it controls. Fourteen out of fourteen. An A.

That grade measures published terms, and it is worth saying what it does not measure. The headline is a first-order price, the subscribe-and-save ladder is unpublished, two funnel pages disagree about which compounding regime fills your prescription, and the NAD+ copy promises outcomes no completed trial has produced. Buy it for what it verifiably is — a month-to-month protocol with no membership and no automatic billing — and budget the second month's price, not the first. The full graded field is at our provider rankings; its immediate neighbors are our HealthRX review and RxSpan MD review.